Silicon Valley giant NVIDIA is teaming up with pharma company AstraZeneca and the University of Florida on new artificial intelligence research projects to boost drug discovery and patient care. They revealed a new drug-discovery model called MegaMoIBART, which aims to "reaction prediction, molecular optimisation and de novo molecular generation." MegaMoIBART will be deployable on NVIDIA's platform for computational drug discovery, known as Clara Discovery, and will use a new kind of technology called transformer neural networks.
Nvidia, a famous Game Tech developer, set out 26 years ago to transform computer graphics. Fueled by the massive growth of the gaming market and its insatiable demand for better 3D graphics, they have evolved the GPU into a computer brain at the intersection of virtual reality, high-performance computing, and artificial intelligence. NVIDIA GPU computing has become the essential tool of our time's da Vincis and Einsteins. Nvidia has redefined what’s possible in gaming. Real-time ray tracing and neural graphics processing come together to create eye-popping images and deliver a level of photorealism never before seen in PC gaming. It brings a new visual dimension to popular games like Call of Duty Modern Warfare, Control, and Watch Dogs: Legion. And it’s opened entirely new possibilities for games like Minecraft — the world’s best-selling video game — where players shape the game’s visuals in real-time.
NVIDIA powers U.S.-based Summit, the world’s fastest supercomputer, as well as the fastest systems in Europe and Japan. More than 130 supercomputers on the TOP500 list are accelerated by NVIDIA, including five of the top 10.
While NVIDIA may be classically associated with the video game industry, it has been working in the health sector for some time. In 2018 the company rolled out its AI platform Clara, designed to use AI to create a virtual medical imaging platform. Since then, the company has launched a Clara AI toolkit for radiologists. The company has also been active in the genomics space. In March, NVIDIA announced its plans to team up with Harvard University on a new AI-based toolkit designed to help researchers gain more access and insights into DNA. Additionally, the tech giant announced it would build a supercomputer for U.K. healthcare researchers.
Why this brings Healthusiasm >> While R&D is the basis of almost all innovations in the biotech and pharma industry, too little radical innovation has been implemented in the process of R&D itself. Drug research and discovery is expensive and time-consuming. The time it takes to bring a molecule to the market varies on average from 8 to 13 years. Part of the explanation can be found that over time 96% of efforts fail during the development of a new drug. Besides, another 90% fall during clinical studies. The increased use of Artificial Intelligence brings a lot of Healthusiasm, as the collaboration between Pfizer and BioNtech has already proven. And in this type of collaboration, there are no more boundaries to the industries. Just see how Johnson & Johnson has partnered with Alibaba labs to bring the right Consumer Health products to the Chinese market faster.